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ABSTRACT:
During their development, tumors acquire multiple capabilities that enable them 
to proliferate, disseminate and evade immunosurveillance. A putative mechanism 
is through the production of the cytokine TGF-β1. We showed in our recent studies 
that T cell-produced TGF-β1 inhibits antitumor T cell responses to foster tumor 
growth raising the question of the precise function of TGF-β1 produced by tumor 
cells in tumor development. Here, using a transgenic model of mammary cancer, 
we report that deletion of TGF-β1 from tumor cells did not protect mice from tumor 
development.  However,  ablation  of  TGF-β1  from  T  cells  significantly  inhibited 
mammary tumor growth. Additionally, absence of TGF-β1 in T cells prevented 
tumors  from  advancing  to  higher  pathological  grades  and  further  suppressed 
secondary tumor development in the lungs. These findings reveal T cells but not 
tumor  cells  as  a  critical  source  of  TGF-β1  that  promotes  tumor  development.
INTRODUCTION
The biology that underlies tumor development is 
complex. Starting from tumor initiation, subsequent 
to cellular transformation, tumors undergo dramatic 
evolution[1]. During this multistep process, studies have 
demonstrated that tumors abandon most of the key features 
associated with normal cells and acquire capabilities that 
serve the ultimate goal of sustaining tumor cell survival 
and proliferation[1]. Indeed, the functional role of 
each of the hallmarks of cancer including proliferative 
signaling, evading growth suppressors, resisting death, 
enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis either directly 
or indirectly promotes tumor cell survival and/or 
proliferation[1]. While these hallmarks are intrinsic 
to tumor cells, growing evidence suggests that it is the 
totality of the tumor microenvironment that determines 
the outcome of carcinogenesis[1-3]. 
The immune system is postulated to recognize 
tumors and to protect the host from tumor development in a 
framework described as cancer immunosurveillance[4-6]. 
The immunosurveillance hypothesis envisaged that this 
function of effector leukocytes in defense against cancer 
would be necessary to maintain tissue homeostasis 
similar to its protective role against pathogenic microbes. 
Studies  in  mice  have  demonstrated  that  deficiency  in 
recombination-activating gene (Rag)-1 or -2 required for 
the development of adaptive immunity results in increased 
frequency, shortened tumor latency, faster tumor growth 
kinetics of chemical-induced sarcomas and increased 
development of a broader spectrum of spontaneous tumors 
compared to age-matched wild type littermates[6-8]. 
Tumors  that  develop  under  immunodeficient  Rag-2 
knockout conditions are rejected when transplanted into 
wild type recipients but develop in hosts depleted of 
CD4+ or CD8+ T cells[7, 9]. Moreover, tumors derived 
from wild type mice are not rejected when transferred into 
either wild type mice or Rag-2-deficient hosts[7, 9]. These 
findings support the immunosurveillance hypothesis and 
further demonstrate that T cells not only mediate tumor 
elimination but can also shape the immunogenicity of 
tumors.
Recently, some effector mechanisms that mediate 
lymphocyte-dependent tumor rejection have been defined. 
Modification of tumor cells to secrete interferon (IFN)-γ 
resulted  in  the  induction  of  persistent  specific  T  cell 
immunity and a CD8+ T cell-dependent tumor rejection 
whereas treatment of wild type mice with antibodies 
to neutralize endogenous IFN-γ led to failed rejection 
of carcinogen-induced tumors[10-12]. In addition to Oncotarget 2011; 2:   1339 - 1351 1340 www.impactjournals.com/oncotarget
IFN-γ, the cytotoxic granule pathway has been shown 
to  be  essential  for  immunosurveillance.  Deficiency  in 
perforin, a crucial pore-forming protein required for the 
killer function of CTLs and natural killer cells results 
in development of fibrosarcomas with reduced latency 
and greater incidence and the mice further show greater 
susceptibility to the development of B cell lymphomas 
in comparison to control wild type mice[13-16]. These 
findings  collectively  underscore  type  1-lymphocyte 
responses in the immunosurveillance of spontaneous and 
MCA-induced tumors. 
However, for the vast majority of tumor types, 
immune-mediated tumor rejection is not observed. 
In a transgenic model of sporadic cancer, the well-
characterized SV40 Tag oncogene is stochastically 
activated leading to tumor development in diverse 
unpredictable tissues[17]. In this model, CD8+ T cells 
recognize the Tag tumor-associated antigen but fail to 
kill target cells when tested in vivo[17]. In the TRAMP 
(transgenic adenocarcinoma of mouse prostate) model 
of  prostate  cancer,  our  recent  findings,  together  with 
previous observations, demonstrated that HRC CD8+ 
T cells specific for the TRAMP self-antigen histone H4 
show functional defects [18, 19]. CD8+ T cells specific to 
tumor antigens have also been described in a subset of 
cancer patients but similar to the animal models, these T 
cells show limited effector activity[20, 21]. These findings 
collectively suggest that T cells are able to recognize their 
cognate tumor antigens but the tumors avoid destruction 
by inducing T cell tolerance.
How tumors initially prime T cell recognition and 
subsequently escape T cell-mediated eradication remains 
poorly understood. Understanding the mechanistic 
underpinnings of T cell tolerance in tumors is fundamental 
to the development of more effective anticancer therapies. 
It is conceivable that the six hallmarks of cancer that 
functionally converge on tumor cell survival and chronic 
proliferation  can  each  influence  antitumor  immune 
response. Indeed, the acquisition of each succeeding 
hallmark capability likely represents an evolutionary 
step whose success would require some escape from 
immune barrier to tumor progression. In addition, studies 
have shown that other cell-biologic behaviors of tumors 
do not favor the generation or function of effector T 
cells.  For  example,  tumors  are  frequently  associated 
with downregulation of MHC class I, impaired antigen 
presentation, lack of costimulation, exapansion and 
activation of suppressor cells which results in defective T 
cell responses to tumors [2, 22, 23]. 
The tumor microenvironment is a dynamic complex 
milieu consisting of the tumor, stromal cells such as 
fibroblasts  and  immune  cells,  vascular  and  lymphatic 
networks and the extracellular matrix. Beside providing 
a supportive stroma, studies have revealed that host cells 
can also influence tumor phenotype by supplying a variety 
of bioactive agents such as growth factors, cytokines 
and chemokines that can modulate tumor growth[1-3, 
24]. It is possible that tumor progression requires these 
secreted factors although given the growth autonomy that 
malignancies acquire during their evolution it remains 
unclear as to what extent tumors depend on these factors 
for their growth. Recent studies have shown that the 
function of these secreted factors in tumors is in large part 
the inhibition of antitumor immune responses [1-3, 24]. 
The identity, sources and mechanisms of how 
some of these secreted factors regulate T cell responses 
to tumors have begun to be understood. In the stochastic 
model of cancer, Willimsky and Blankenstein showed 
that  the  development  of  defective  tumor-specific 
T  cell  responses  is  coincident  with  loss  of  IFN-γ 
response and the acquisition of elevated levels of the 
cytokine  transforming  growth  factor  (TGF)-β1  in  the 
circulation[25].  Systemic  levels  of  TGF-β1  are  also 
associated with T cell dysfunction in cancer patients 
where it is a negative prognostic indicator[26]. TGF-β is a 
family of three isoforms comprising TGF-β1, 2 and 3. It is 
secreted as an inactive latent ligand that requires activation 
catalyzed by a variety of factors including proteases and 
integrins [27-31]. Once the active ligand is liberated, it 
binds the serine or threonine kinases TGF-β type I (TGF-
βRI) and type II (TGF-βRII) receptors, which recruit and 
phosphorylate Smad2 and Smad3 transcription factors[28, 
29, 32]. Activated Smad2 and Smad3 proteins dimerize 
and complex with Smad4 and translocate to the nucleus 
to regulate Smad-dependent genes[28, 29, 32]. Studies 
have shown that TGF-β exerts antiproliferative effects on 
epithelial cells by transcriptional repression of c-Myc and 
induction of inhibitors of cyclin-dependent kinases, which 
are important for cell cycle entry and progression[29]. 
In  addition,  TGF-β  profoundly  represses  lymphocyte 
proliferation and differentiation and autoreactive 
function[28, 32-37]. 
In a variety of tumor types, TGF-β has been suggested 
to play an important role in tumor progression[38]. At 
the early stage of tumor development, TGF-β is thought 
to regulate cellular homeostasis by enforcing cytostasis, 
differentiation and apoptosis of tumor cells[39, 40]. 
Indeed, transgenic expression of a dominant negative 
mutant  of  TGF-βRII  (DNR)  in  prostate  epithelium 
accelerates tumor development and reduces tumor latency 
in TRAMP mice, underscoring a suppressive function of 
TGF-β in tumorigenesis[41]. However, studies show that 
some tumors can circumvent the suppressive effects of 
TGF-β via mutations in TGF-β receptors or downstream 
alterations that disable the tumor suppressor arm of the 
TGF-β pathway[42, 43]. Autocrine TGF-β signaling is 
then thought to promote tumor progression via regulation 
of the invasion-metastasis cascade involving epithelial-
to-mesenchymal transition, invasion of regional tissue, 
dissemination and metastatic colonization [29]. 
In contrast to this prevailing model that emphasizes 
the effect of TGF-β signaling on tumors, recent studies Oncotarget 2011; 2:   1339 - 1351 1341 www.impactjournals.com/oncotarget
suggest  that  TGF-β  regulation  of  T  cell  responses  to 
tumors is an integral part of tumor development[18, 
44-47]. Consistent with these observations, we recently 
demonstrated that failure to control TRAMP tumor 
growth by adaptive immunity arises from T cell-intrinsic 
TGF-β signaling that initiates at the tumor-draining lymph 
nodes[18]. TRAMP tumors, like most tumors, are sensitive 
to TGF-β ligands but the requirement of TGF-β signaling 
for the development of these tumors remains to be 
determined. Nonetheless, these observations suggest that 
T cell-intrinsic TGF-β signaling probably exercises greater 
control on tumor development in comparison to tumor 
responsiveness to TGF-β. Importantly, it can be inferred 
from these findings that the varied tumor immunoevasion 
strategies and the cell-intrinsic hallmarks of cancer can be 
overruled by blocking TGF-β signaling in T cells. 
Diverse cell types in normal tissues produce TGF-β1 
and its production may further be upregulated in response 
to tumor development [34, 48-50]. There is, however, a 
strong sense that tumor secretion of TGF-β1 is a major 
mechanism of T cell tolerance [44, 51-53]. It has been 
shown that overexpression of an active form TGF-β1 in 
an immunogenic tumor cell results in inhibition of CTL-
mediated tumor rejection when inoculated into mice[53]. 
On the basis of this overexpression study and other 
succeeding studies, it was concluded that tumors produce 
TGF-β1 to evade immune control[44, 51, 52]. Tumor 
secretion of TGF-β1 is therefore conceptualized to dampen 
T cell reactivity at the tumor microenvironment where T 
cells are exposed to large quantities of TGF-β1 produced 
by tumor cells. Contrary to this view, we demonstrated in 
our recent studies that T cell-specific deletion of TGF-β1 
protected mice against tumor growth and metastasis 
independent of TGF-β1 produced by tumor cells[18]. In 
Tgfb1f/n Cd4cre-TRAMP mice, we found that protective 
tumor immunity was associated with T cell differentiation 
into IFN-γ- and granzyme (Gzm)B-producing effectors in 
the tumor draining lymph nodes and prostate[18] in line 
with reports showing that TGF-β1 suppressess antitumor 
immunity by transcriptional repression of the CTL 
program including the expression of IFN-γ and GzmB[54]. 
These studies provide compelling evidence that T cell 
TGF-β1 fosters T cell tolerance in tumors and is essential 
for tumor growth. Importantly, these observations do not 
support an essential role for TGF-β1 produced by tumor 
cells in the development of these tumors. Nevertheless, 
in the absence of experimental approaches that assess the 
definitive function of tumor-produced TGF-β1, evidence 
against  tumors  as  the  critical  source  of  TGF-β1  that 
inhibits immunosurveillance would be incomplete.
 In this study, we addressed the specific function 
of  tumor-produced TGF-β1  in  tumor  development  by 
crossing mice carrying floxed/null alleles of Tgfb1 to the 
Mmtvcre deleter mouse strain in which cre recombinase 
directs deletion of the Tgfb1 allele from mammary 
epithelium[55]. The Tgfb1f/n Mmtvcre line and the Tgfb1f/n 
Cd4cre line used in our previous studies[18] were further 
crossed to the polioma middle T antigen (PyMT) mice 
in which the transgenic mice develop highly aggressive 
mammary adenocarcinoma that metastasizes to the 
lungs[56]. We found that tumor growth and pulmonary 
metastasis were comparable between Tgfb1f/n Mmtvcre-
PyMT and control Tgfb1f/n-PyMT littermates. However, 
deletion  of  TGF-β1  from  T  cells  inhibited  tumor 
development and protected PyMT mice from pulmonary 
metastasis. These findings establish that TGF-β1 produced 
by T cells, but not tumor cells, is required for tumor 
growth and metastasis in PyMT mice. These observations 
further extend the generality of the requirement of TGF-β1 
produced by T cells in the development of spontaneous 
tumors.ResultsDeletion of tumor-produced TGF-β1 does 
not affect tumor growth and metastasis in PyMT mice
In addition to the cell intrinsic hallmarks of cancer, 
tumors require other enabling mechanisms to achieve 
their survival and chronic replication program[1]. Studies 
show that the ability to evade immune eradication via 
TGF-β-mediated tolerance induction is a crucial survival 
mechanism for tumors[1, 2, 39, 48, 57, 58]. Recently, 
we demonstrated a non-redundant function of TGF-β1 
produced by T cells in tumor development [18], which 
leaves open the exact function of TGF-β1 produced by 
tumors in tumor development. To rigorously test the 
requirement of tumor TGF-β1 for the development of 
spontaneous tumors, we employed genetic approach 
targeting  TGF-β1  produced  by  tumor  cells.  To  this 
end, we bred mice carrying floxed/null alleles of Tgfb1 
(Tgfb1f/n) mice to the Mmtvcre deleter strain in which 
the cre recombinase instructs allelic recombination in 
mouse mammary epithelium[55]. Tgfb1f/n  Mmtvcre 
mice were further crossed to PyMT mice to obtain 
Tgfb1f/n  Mmtvcre-PyMT mice. By RT-PCR analysis, 
we verified that TGF-β1 is specifically deleted in tumor 
cells but not lymph node cells of tumor-bearing Tgfb1f/n 
Mmtvcre-PyMT mice (Figure 1A). To assess the effect 
of TGF-β1 deficiency in tumor cells on the development 
of autochthonous mammary tumors, we monitored the 
mice for tumor growth. We found no differences between 
Tgfb1f/n  Mmtvcre-PyMT and their littermates Tgfb1f/n-
PyMT when evaluated for tumor latency, tumor burden at 
the age of 20 weeks or the age at which the tumors reach 
the predetermined size of 2500 mm3 (Figure 1B and 1C). 
Tumor pathogenesis has remarkable complexity that 
can manifest itself at more than one stage in the evolution 
of tumors. Thus, primary tumor size per se may not capture 
the full functional spectrum of a given signaling pathway 
on carcinogenesis. Metastatic dissemination is the primary 
cause of tumor-associated death in a very high proportion 
of cancer patients[59]. Tumor progression in the PyMT 
model recapitulates key features of human breast cancer 
including high incidence of secondary tumor development 
in the lung[56]. When Tgfb1f/n Mmtvcre-PyMT mice and 
the Tgfb1f/n-PyMT cohorts with comparable tumor burden Oncotarget 2011; 2:   1339 - 1351 1342 www.impactjournals.com/oncotarget
were evaluated for pulmonary metastasis, we found 
comparable tumor burden in the lungs (Figure 1D). These 
observations collectively suggest that tumor growth and 
metastasis in PyMT mice do not require TGF-β1 produced 
by  tumor  cells.Inactivation  of  T  cell  TGF-β1  inhibits 
tumor development in PyMT mice
By virtue of the widely reported role of TGF-β1 
produced by tumor cells in tumor development[44, 51-53], 
it was quite unexpected to find that deletion of TGF-β1 
from tumor cells neither affected primary tumor growth 
nor tumor metastasis compared to control littermates 
(Figure 1B, 1C and 1D). Next, we turned out attention to 
the role of TGF-β1 produced by T cells in the development 
of PyMT tumors. In our earlier studies, we demonstrated 
that T cells provide the critical source of TGF-β1 that 
promotes immunotolerance and tumor development in the 
TRAMP model of prostate cancer[18]. Specifically, we 
demonstrated that the inhibitory effect of TGF-β1 resides 
in TGF-β1 produced by Ox40+ subpopulation of T cells 
that consists predominantly of activated CD4+ T cells 
and CD4+Foxp3+ T cells (Tregs)[60]. Thus, we became 
interested in the broader applicability of T cell produced 
TGF-β1 in tumor development. To investigate the function 
of T cell-derived TGF-β1 in mammary carcinogenesis, we 
Table 1: Pathologic scoring for stages of tumor development in the mammary glands of littermates of Tgfb1f/n Cd4cre-
PYMT and Tgfb1f/n PYMT mice at 20 weeks of age. The values are average percentages of the stages of 4 pairs of littermates 
reviewed by identifying tumor stages by area and expressing each stage as a % ± SEM The normal % represents the percentage area within 
the mammary gland with no visible tumor.
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Figure 1: Absence of TGF-β1 produced by mammary tumor cells does not affect tumor growth. (A) RT-PCR analysis 
of Tgfβ1 and Hprt expression from FACS-sorted tumor cells of control Tgfb1f/n PYMT mice, and from tumor cells and lymph node cells 
of Tgfb1f/n Mmtvcre-PYMT mice. LN; lymph node (B) Total tumor burden in all mammary glands of Tgfb1f/n Mmtvcre-PYMT (n=9) and 
control Tgfb1f/n PYMT (n=9) mice at 20 weeks of age. Tumor volume was calculated using the formula L x W2x 0.52 (where L is the longest 
diameter and W is the smallest diameter.) (C) The age at which Tgfb1f/n Mmtvcre-PYMT (n=9) and littermate control Tgfb1f/n PYMT mice 
(n=9) achieved the predetermined tumor burden of 2500 mm3. (D) Total pulmonary metastatic nodules in Tgfb1f/n Mmtvcre-PYMT (n=5) 
and control Tgfb1f/n PYMT (n=6) mice were assessed at a tumor burden of 2500 mm3. The p values between the two groups of tumor burden 
(B) age (C) and number of metastatic nodules (D) are shown (Students t-test). Oncotarget 2011; 2:   1339 - 1351 1343 www.impactjournals.com/oncotarget
crossed the Tgfb1f/n Cd4cre line to PyMT mice to generate 
Tgfb1f/n Cd4cre-PyMT mice. When evaluated for tumor 
growth, we found that tumor burden at 20 weeks of age 
was significantly lower in Tgfb1f/n Cd4cre-PyMT mice 
compared to control Tgfb1f/n-PyMT mice (Figure 2A). 
In cancer patients, higher pathological grade correlates 
with poorer survival outcome[62]. By histopathological 
analysis, we found that, on average, 40% of the mammary 
glands in Tgfb1f/nCd4cre-PyMT mice were normal 
whereas over 60% of the mammary glands analyzed in 
Tgfb1f/n-PyMT mice had histological grade III or higher 
(Table 1). Thus a considerable proportion of the mammary 
glands in Tgfb1f/nCd4cre-PyMT mice were prevented 
from advancing to higher histological grades. In contrast 
In addition, the tumors in Tgfb1f/n Cd4cre-PyMT mice 
grew at a slower rate reaching a volume of 2500 mm3 in 
approximately 25 weeks of age whereas it took Tgfb1f/n-
PyMT mice only 20 weeks to reach the same tumor burden 
(Figure 2B). Thus, tumor latency is increased and tumor 
growth kinetics reduced in Tgfb1f/n Cd4cre-PyMT mice 
compared to littermate Tgfb1f/n-PyMT mice.
The requirement for mammary tumor growth 
on TGF-β1 produced by T cells is consistent with our 
previous reports[18]. However, in the TRAMP model, it 
was not possible to select mice with comparable tumor 
burden, a parameter that has been shown to be coupled 
to metastatic risk[61]. We circumvented this limitation by 
employing B16-OVA and EL-4 metastasis assay where 
we found that, similar to primary tumor growth, T cell-
produced TGF-β1 was required for the metastasis of these 
tumors[18]. Although experimental metastasis using B16-
OVA and EL-4 tumors are well-established assays, they 
nonetheless have the important caveat of not recapitulating 
physiological metastasis. We found that whereas tumor 
development in Tgfb1f/n-PyMT mice evoked significant 
secondary tumor development in the lungs, pulmonary 
tumor metastasis was largely inhibited in Tgfb1f/nCd4cre-
PyMT mice that had reached similar primary tumor 
burden as Tgfb1f/n-PyMT mice (Figure 2C and 2D). These 
results collectively establish that TGF-β1 produced by T 
cells promotes tumor growth and progression and further 
facilitates secondary niche colonization in PyMT mice.
DiscussionTumor growth is a complex phenomenon. In 
addition to the initiating oncogenic signals, tumors require 
Figure 2: Deficiency of T cell TGF-β1 inhibits mammary tumor development. (A) Total tumor burden in all mammary glands 
of Tgfb1f/n Cd4cre-PYMT (n=14) and control Tgfb1f/n PYMT (n=14) mice at 20 weeks of age. Tumor volume was calculated using the 
formula L x W2x 0.52 (where L is the longest diameter and W is the smallest diameter.) (B) The age at which Tgfb1f/n Cd4cre-PYMT (n=14) 
and littermate control Tgfb1f/n PYMT mice (n=14) achieved the predetermined tumor burden of 2500mm3. Tumor volume was calculated 
using the formula L x W2x 0.52 (where L is the longest diameter and W is the smallest diameter.) (C) Total pulmonary metastatic nodules in 
Tgfb1f/n Cd4cre-PYMT (n=9) and control Tgfb1f/n PYMT (n=9) mice were assessed at a tumor burden of 2500 mm3 .The p values between 
the two groups of tumor burden (A) age (B) and number of metastatic nodules (C) are shown (Students t-test). * depicts statistically 
significant difference. (D) Histological analysis of sections of lungs of Tgfb1f/n Cd4cre-PYMT and Tgfb1f/n PYMT at a tumor burden of 
2500 mm3. Sections of representative lungs from Tgfb1f/n PYMT and Tgfb1f/n Cd4cre-PYMT mice were stained with hematoxylin and eosin. 
Black arrows indicate metastatic nodules. 
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additional capabilities, which along with a permissive 
environment, facilitate tumor cell survival, proliferation 
and metastasis[1]. Studies have implicated the cytokine 
TGF-β1 in tumor initiation and progression[1, 48, 58]. 
However, because diverse cell types produce TGF-β1, 
defining its cellular source for tumor growth has been 
challenging. Using a spontaneous model of mammary 
cancer,  we  demonstrated  that  deleting  TGF-β1  from 
tumors did not protect mice against tumor development. 
However, inactivation of TGF-β1 in T cells significantly 
increased tumor latency and inhibited tumor growth. 
Additionally, we showed that T cell produced TGF-β1 is 
necessary for tumor progression to higher pathological 
grades and is further required for the development of 
secondary  tumors  in  the  lungs.  These  findings  reveal 
T cells as the critical source of TGF-β1 that promotes 
mammary tumor development.
TGF-β1 has long been recognized as a cytokine that 
promotes tumor development and it is thought that this 
cytokine mediates tumor growth via its direct effect on 
tumors[1, 48, 58]. Indeed, mice that express a dominant 
negative  mutant  of  TGF-βRII  (DNR)  in  the  prostate 
epithelium have accelerated tumor development of 
TRAMP tumors [41], supporting the function of TGF-β1 
as an enforcer of cytostasis in a variety of cell types[48, 
57]. Yet, to what degree physiological TGF-β signaling 
influences  tumor  development  remains  incompletely 
resolved. Studies show that another important target of 
TGF-β1  in  tumors  is  antitumor  immune  responses[2, 
39, 48, 63]. In agreement with this observation, we 
demonstrated recently that T cell responsiveness to TGF-β 
induces T cell tolerance in TRAMP mice[18]. Accordingly 
attenuation of TGF-β signaling in T cells protects TRAMP 
mice from tumor development whereas tumors develop 
normally in control TRAMP mice[18]. In PyMT mice 
in which TGF-β signaling is blocked in T cells, tumor 
development is similarly inhibited (our unpublished 
observations). While there is evidence suggesting that 
TGF-β sensitivity by tumors plays an important role for 
tumor initiation and progression, our data support a model 
in which the inhibitory effect of TGF-β on the immune 
system is more important and ultimately determines tumor 
growth and its blockade in T cells can override these 
growth advantages TGF-β signaling confers to tumors. 
A crucial observation in this study is the finding that 
deletion of TGF-β1 from tumor cells did not have any 
consequences on tumor latency or progression in PyMT 
mice. Furthermore, we found that tumor-derived TGF-β1 
is dispensable for CD4+ and CD8+ T cell differentiation in 
PyMT mice (data not shown). Many cell types produce 
TGF-β1  and  because  of  the  broad  distribution  of  the 
TGF-β  receptors,  almost  every  cell  type  responds  to 
this cytokine[29]. Our findings are in stark contrast to 
the widely held hypothesis that tumor-derived TGF-β1 
promotes T cell tolerance and tumor development [2, 
38, 44, 48, 52, 53, 64]. The favored mechanism is that 
tumors, by mechanisms largely unknown but probably 
involve hypoxia and/or inflammation, acquire the ability to 
abundantly produce TGF-β1 during their evolution which 
enables the tumors to progress via autocrine effects on 
tumors and paracrine suppression of immunosurveillance. 
This model derives from findings described in a study 
showing that overexpression of active TGF-β1 cDNA in 
immunogenic tumors increased their tumorigenicity and 
evaded CTL-mediated eradication[53]. Succeeding studies 
further showed improved antitumor immunity via antibody 
neutralization of TGF-β or tumor cell expression of soluble 
TGF-βRII. However, it is evident that a requirement for 
tumor-derived TGF-β1 in immunotolerance and tumor 
development cannot be deduced from these observations. 
Consistent with our findings, a more recent study provided 
evidence  that  shRNA-mediated  knockdown  of  tumor-
derived  TGF-β1  did  not  inhibit  tumor  development 
in tumor transplantation studies whereas tumor cell 
expression  of  soluble TGF-βRII  did[54]. Whether  the 
development of other spontaneous tumors and, more 
importantly, human cancers will also prove to be 
independent of tumor-derived TGF-β1 as demonstrated 
for TRAMP [18] and PyMT tumors is open for future 
inquiries.
As  opposed  to  tumor-derived  TGF-β1,  deletion 
of TGF-β1 from T cells significantly increased tumor 
latency and suppressed tumor development in PyMT mice. 
However unlike Tgfb1f/nCd4cre-TRAMP mice where 
tumor protection was associated with frank increases 
in the expression of the effector molecules IFN-γ and 
GzmB by T cells in the tumor-draining lymph nodes 
and prostates[18], tumor protective immunity in Tgfb1f/
nCd4cre-PyMT mice was associated with moderately 
increased expression of these effector molecules in Tgfb1f/
nCd4cre-PyMT mice compared to Tgfb1f/n-PyMT mice 
(data not shown). The IFN-γ and the killer cell cytotoxic 
granule pathways are essential for the rejection of a 
variety of tumor types[7, 9, 10, 13-15]. However, to what 
extent the observed responses account for the inhibition 
of tumor development in these mice remains unclear. 
Nonetheless, these observations bring to one additional 
tumor in which deletion of TGF-β1 from T cells protects 
mice against spontaneous tumors. These findings however 
raise an important question: what special attributes endow 
TGF-β1 produced by T cells with the ability to suppress 
antitumor immune responses? One possible answer lies in 
the biological properties of TGF-β1. Because TGF-β1 is 
secreted as an inactive latent ligand, it requires activation 
catalyzed by multiple processes. One well-established in 
vivo mechanism of activation is via dendritic cell (DC)-
expressed  αvβ8  integrin[31].  Therefore,  we  speculate 
that in the process of priming naïve T cells in the tumor-
draining lymph nodes, T cells secrete TGF-β1, which 
in  turn  regulates  T  cell  responses  following  TGF-β1 
activation by DCs. There are two data sets to support this 
speculation. First, in the TRAMP model, we previously Oncotarget 2011; 2:   1339 - 1351 1345 www.impactjournals.com/oncotarget
found that tumor development triggers enhanced TGF-
β-dependent Smad2 and Smad3 phosphorylation in the 
tumor-draining lymph nodes compared to other tissues 
examined including the prostate[18] . We further showed 
that TGF-β inhibition of T cell priming in the tumor-
draining lymph nodes is contributed partly by TGF-β1 
produced by T cells[18]. Second, and more recently, we 
found that the inhibitory effect of T cell TGF-β1 resides 
predominantly in activated Ox40+ T cells[60]. In an 
unrelated process, data from pharmacokinetic studies have 
demonstrated that active TGF-β1 has an extremely short 
half-life of 2-3 min[65]. This short half-life, combined 
with the ubiquitous expression of TGF-β receptors by 
tumors and cells in the tumor stroma, makes it unlikely 
for tumor-derived TGF-β1 to successfully diffuse to the 
tumor-draining lymph nodes to regulate T cell responses. 
The propensity of primary tumors to undergo EMT, 
become invasive, to seed and colonize distant niches has 
important clinical implications[39, 59]. Tumor metastasis 
accounts for over 90% of cancer-related deaths[59]. 
In human breast cancer, a recent study demonstrated 
that TGF-β plays a key role in priming tumor cells for 
dissemination and adaptation to secondary locations 
such as the lung although the cellular source of TGF-β 
that mediates this process was not investigated[57]. We 
previously found that TGF-β1 produced by T cells is 
necessary for lung and peritoneal cavity colonization in 
experimental metastasis assays[18]. In this report, we 
have further extended these findings by demonstrating 
that pulmonary metastasis of PyMT tumors is dependent 
on TGF-β1 produced by T cells. In agreement with our 
previous observations[18], secondary tumor development 
in the lungs was comparable between Tgfb1f/n-PyMT and 
Tgfb1f/nMmtvcre-PyMT mice, formally demonstrating 
that TGF-β1 produced by these tumors is dispensable 
for  autochthonous  tumor  metastasis.  These  findings 
collectively refine and expand upon our previous findings 
showing  that  TGF-β1  produced  by  T  cells  but  not 
tumors crucially participates in tumor development by 
suppressing antitumor immune responses to foster primary 
tumor growth and metastatic dissemination. 
The elucidation of the molecular mechanisms 
that underlie carcinogenesis has led to rapid informed 
development of many mechanism-based therapies 
for cancer. Typically, these therapeutic agents inhibit 
molecular targets that regulate one or more cancer 
hallmark capabilities. Experimental evidence shows 
that because of redundancy in signaling pathways or the 
acquisition of new genetic or epigenetic changes, tumors, 
more often than not, adapt to the therapeutic agent[66]. 
Thus, successful eradication of cancer will require various 
drug combinations that target parallel signaling pathways 
that undergird one or more cancer hallmarks. Given the 
side effects associated with inhibiting a single molecular 
target, this goal seems so far away if not impossible.
Immunotherapy is an emerging viable alternative for 
cancer therapy. Recent clinical and animal model studies 
have demonstrated the effectiveness and durability of 
cancer immunotherapy[67]. The success of Ipilimumab/
Yervoy, recently approved by the FDA for the treatment 
of metastatic melanoma is a sterling example of how the 
immune system can be harnessed to fight cancer. The 
TGF-β pathway is an important target for therapeutic 
intervention in cancer. Indeed, various strategies to 
modulate TGF-β signaling are already in different stages 
of clinical evaluation including neutralizing antibodies, 
silencing oligonucleotides and small molecule inhibitors. 
All  these  approaches  lack  specificity  because  their 
mechanism is based on targeting TGF-β systemically. 
Our findings suggest that strategies that deliver TGF-β 
blockade  specifically  to  T  cells  alone  can  alleviate 
immunotolerance and potentially overrule the cell-
intrinsic hallmarks of cancer. Such rational approaches 
would not only leverage antitumor immune response but 
also preserve the cytostatic effects of TGF-β on tumors for 
cancer eradication. Methods
Mice
PyMT  and  mice  with  floxed  and  null  alleles  of 
Tgfb1 gene have previously been described[56, 68]. 
PyMT mice were backcrossed to C57BL/6 background 
for 10 generations. Crossing mice with floxed and null 
alleles of Tgfb1 gene (f/n) with CD4cre mice generated 
Tgfb1f/nCd4cre mice having T cell-specific deletion of 
TGF-β1.  We  subsequently  generated  Tgfb1f/nCd4cre-
PyMT mice by crossing Tgfb1f/nCd4cre to PyMT mice. 
Tumor  cell-specific  deletion  of TGF-β1  was  achieved 
by crossing PyMTf/n mice with Mmtvcre mice (Jackson 
Laboratory, stock#003553) that had been backcrossed to 
C57BL/6 background for 10 generations. All mice were 
maintained under specific pathogen-free conditions, and 
animal experimentation was conducted in accordance with 
MSKCC institutional guidelines.
Reverse transcription PCR
  RNA  was  prepared  from  FACS-sorted  tumor 
cells  and  lymph  node  cells  with  miRNeasy  kit 
(Qiagen),  and  was  reverse  transcribed  into  cDNA. 
cDNA was amplified with the primer set for TGF-b1 
gene: 5’-ATCCCACCTTTGCCGAGGGTT-3’, and 
5’-GCTTCCCGAATGTCTGACGTA-3’.Histopathology 
and pulmonary nodule enumeration
Mammary  glands  and  lungs  from  sacrificed 
animals  were  fixed  in  10%  buffered  neutral  formalin 
and embedded in paraffin. For macroscopic pulmonary 
nodule  analysis,  lungs  were  fixed  in  Bouin’s  fixative 
and the number of metastases counted with a dissecting 
microscope. For histopathological analyses, 4-5 μm tissue 
sections were routinely stained with haematoxylin and Oncotarget 2011; 2:   1339 - 1351 1346 www.impactjournals.com/oncotarget
eosin and microscopically examined for the stages of 
tumor development. Microscopic samples were semi-
quantitatively reviewed by identifying tumor stages by 
area and each stage was expressed as a percentage of the 
tissue sample. Tumor stage classification followed the 
criteria as previously described[69].Statistical analysis
Student’s t test was used to calculate statistical 
significance for difference in a particular measurement 
between groups. A p value of < 0.05 was considered 
statistically significant.
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